A platform, not a single assay
Our technical foundation spans bacterial, yeast, insect and mammalian cell-free expression, allowing the expression environment to match the molecule and experiment.
Protein design is accelerating. Experimental validation and manufacturing still move at the speed of cell culture. Liberum is building cell-free systems that close that gap across bacterial, yeast, insect and mammalian biology.
Liberum is rapidly becoming the expression infrastructure behind AI labs, cloud labs and next-generation protein discovery.
Sequence generation is becoming abundant. The scarce layer is turning those sequences into physical molecules and reliable experimental data quickly enough to keep pace.
Our technical foundation spans bacterial, yeast, insect and mammalian cell-free expression, allowing the expression environment to match the molecule and experiment.
Liberum connects sequence generation to physical protein and measured phenotype, creating infrastructure for directed evolution, automated laboratories and AI-driven protein engineering.
Antibody-fragment reagents are available through cell-free.com, while Fynd extends our mammalian technology into rapid full-length IgG production.
The same core capability supports affinity maturation and experimental data generation, antibody production, and rapid vaccine antigen manufacturing.
Liberum has four active patent filings protecting core aspects of our technology platform. Additional details are available under confidentiality as part of investor diligence.
Liberum is backed by SOSV, TechU Ventures and a large pharmaceutical company. We are building toward a world where protein expression is infrastructure, not a bottleneck.
Tell us what you are trying to express, evolve or manufacture.